GSK Makes ADC Pipeline Comeback With Mersana Deal
Pays $100m Upfront
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
